Pharmaceuticals Market Research Reports & Industry Analysis

Pharmaceuticals refer to compounds manufactured for use as a medicinal drug. Companies active in the pharmaceutical industry are involved in development, production and marketing of pharmaceuticals.

The global market for pharmaceuticals is demonstrating a substantial growth in Latin America and Asia, but is relatively stable in Europe. The worldwide market is assessed at about USD 300 billion yearly. The USA, Japan, Germany, France and China are the top pharmaceutical markets. The pharmaceutical industry benefits from the ageing population; new medical discoveries and new drugs approvals; the increased number of chronic, degenerative and heart diseases, and cancer.

The research reports of this Catalogue cover all the major categories within global, regional and local pharmaceuticals markets. The reports offer overviews of the market trends, drivers; factors contributing to market growth. The challenges faced by industry participants, analyses of the top companies involved in the marketplace, and the key market news are provided in the reports.

Found 14412 publications
Austria Pharmaceuticals and Healthcare Report Q4 2014 US$ 1,295.00

... updates BMI View: BMI has upwardly revised its pharmaceutical and healthcare forecasts for Austria, reflecting the country's improving economic prospects ... country had limited effect in both volume and value sales of pharmaceuticals, indicating its attractiveness even as the European economy remains subdued ...

Sep, 2014 68 pages
Tolvaptan - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and results This report covers: International Nonproprietary Name: Tolvaptan indications: Treatment of hypervolemic and euvolemic hyponatraemia secondary to syndrome of inappropriate antidiuretic-hormone secretion and congestive heart failure innovator: Otsuka Pharm (Samsca); Aspen (Samsca) Country ...

Sep, 2014
Tolvaptan - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... and results This report covers: International Nonproprietary Name: Tolvaptan indications: Treatment of hypervolemic and euvolemic hyponatraemia secondary to syndrome of inappropriate antidiuretic-hormone secretion and congestive heart failure innovator: Otsuka Pharm (Samsca); Aspen (Samsca) Country ...

Sep, 2014
Tolvaptan - Comprehensive patent search US$ 6,200.00

... and results This report covers: International Nonproprietary Name: Tolvaptan indications: Treatment of hypervolemic and euvolemic hyponatraemia secondary to syndrome of inappropriate antidiuretic-hormone secretion and congestive heart failure innovator:Otsuka Pharm (Samsca); Aspen (Samsca) Country ...

Sep, 2014
Simeprevir - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and results This report covers: International Nonproprietary Name: Simeprevir indications: Treatment of chronic hepatitis C infection in combination with Peginterferon alfa and Ribavirin, or with Sofosbuvir and optionally Ribavirin innovator: Janssen Pharm (Olysio, Galexos) Country Coverage: ...

Sep, 2014
Simeprevir - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... and results This report covers: International Nonproprietary Name: Simeprevir indications: Treatment of chronic hepatitis C infection in combination with Peginterferon alfa and Ribavirin, or with Sofosbuvir and optionally Ribavirin innovator: Janssen Pharm (Olysio, Galexos) Country Coverage: Albania ...

Sep, 2014
Mirabegron - Comprehensive patent search US$ 6,201.00

... , save searches and results This report covers: International Nonproprietary Name: Mirabegron indications: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency innovator:Astellas (Myrbetriq, Betmiga) Country coverage: The In-depth search contains ...

Sep, 2014
Ledipasvir - Comprehensive patent search US$ 7,500.00

... searches and results This report covers: International Nonproprietary Name: Ledipasvir indications: Treatment of chronic HCV infection in combination with Sofosbuvir innovator:Gilead Country coverage: The In-depth search contains patents from territories that are individually verified and monitored ...

Sep, 2014
Elvitegravir - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... results This report covers: International Nonproprietary Name: Elvitegravir indications: Treatment of HIV-1 infection in combination with Cobicistat, Emtricitabine and Tenofovir disoproxil fumarate, or Ritonavir-boosted protease inhibitors or other antiretrovirals innovator: Gilead (Stribild); Gilead ( ...

Sep, 2014
Elvitegravir - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... results This report covers: International Nonproprietary Name: Elvitegravir indications: Treatment of HIV-1 infection in combination with Cobicistat, Emtricitabine and Tenofovir disoproxil fumarate, or Ritonavir-boosted protease inhibitors or other antiretrovirals innovator: Gilead (Stribild); Gilead ( ...

Sep, 2014
Elvitegravir - Comprehensive patent search US$ 7,500.00

... This report covers: International Nonproprietary Name: Elvitegravir indications: Treatment of HIV-1 infection in combination with Cobicistat, Emtricitabine and Tenofovir disoproxil fumarate, or Ritonavir-boosted protease inhibitors or other antiretrovirals innovator:Gilead (Stribild); Gilead (Vitekta); ...

Sep, 2014
Aflibercept - Comprehensive patent search US$ 9,300.00

... of neovascular wet age-related macular degeneration; Treatment of macular edema following central retinal vein occlusion; Treatment of metastatic colorectal cancer that is resistant to or has progressed following an Oxaliplatin-containing regimen in combination with 5-Fluorouracil, Leucovorin and Irinotecan ...

Sep, 2014
Abatacept - Comprehensive patent search US$ 9,300.00

... indications: Treatment of adult rheumatoid arthritis, optionally in combination with DMARDs optionally other than TNF antagonists; Treatment of juvenile idiopathic arthritis, optionally in combination with Methotrexate; Treatment of juvenile rheumatoid arthritis innovator:Bristol Myers Squibb (Orencia) ...

Sep, 2014
Zosano, Inc. - Product Pipeline Review - 2014 US$ 1,500.00

... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Zosano, Inc.’s pipeline products ... drug targets and therapeutic classes in the Zosano, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas Exploit ...

Sep, 2014 23 pages
Recepta Biopharma S.A. - Product Pipeline Review - 2014 US$ 1,500.00

... and its locations and subsidiaries The report reviews current pipeline of Recepta Biopharma S.A.’s human therapeutic division and enlists all their major ... the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Recepta Biopharma S.A.’s pipeline products ...

Sep, 2014 26 pages
Q Chip Ltd. - Product Pipeline Review - 2014 US$ 1,500.00

... business description, key information and facts, and its locations and subsidiaries The report reviews current pipeline of Q Chip Ltd.’s human therapeutic ... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Q Chip Ltd.’s pipeline products ...

Sep, 2014 21 pages
Genextra S.p.a. - Product Pipeline Review - 2014 US$ 1,500.00

Genextra S.p.a. - Product Pipeline Review - 2014 SUMMARY Global Markets Direct’s, ‘Genextra S.p.a. - Product Pipeline Review - 2014’, provides an overview of the Genextra S.p.a.’s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic ...

Sep, 2014 23 pages
Arthrogen BV - Product Pipeline Review - 2014 US$ 1,500.00

Arthrogen BV - Product Pipeline Review - 2014 SUMMARY Global Markets Direct’s, ‘Arthrogen BV - Product Pipeline Review - 2014’, provides an overview of the Arthrogen BV’s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental ...

Sep, 2014 21 pages
Global Erectile Dysfunction Drugs Market 2014-2018 US$ 2,500.00

... and effective therapies. TechNavio's analysts forecast the Global Erectile Dysfunction Drugs market to decline at a CAGR of 4.47 percent over the period 2013- ... . The report includes a discussion of the key vendors operating in this market. Key Regions Americas APAC EMEA Key Vendors Apricus Biosciences ...

Sep, 2014 77 pages
Global Pneumococcal Vaccines Market 2014-2018 US$ 2,500.00

... disease caused by different serogroups of Streptococcus pneumonia. TechNavio's report, the Global Pneumococcal Vaccines Market 2014-2018, has been prepared based on an in-depth ... report Key Questions Answered in this Report What will the market size be in 2018 and what will the growth rate be? What are ...

Sep, 2014 64 pages
Pediatric Drug Development - Regulatory Challenges and Commercial Opportunities US$ 2,995.00

... Pediatric vaccines Key Reasons to Purchase Reviews the current regulatory landscape and helps sponsors to understand the potential impact of FDA SIA regulations ... plans; Identifies the key challenges associated with pediatric drug development and the ways to overcome these hurdles; Assesses what issues ...

Jul, 2014 64 pages
Adaptive Licensing - A Holistic Approach to Drug Development and Regulation US$ 2,995.00

... and registries. Data from ongoing RCTs, and the more robust data from post-license surveillance studies are used to determine full ... and political changes will be necessary to realize the full potential of AL. Scope Adaptive Licensing: Overview Introduction A Declining Industry – How AL can tackle issues ...

Jul, 2014 79 pages
Global Cancer Vaccines Market & Pipeline Analysis US$ 2,400.00

... present day do not have effective treatments. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into ... Pipeline by Phase, Indication, Company & Country Global Cancer Vaccine Clinical Pipeline: 289 Vaccines Marketed Cancer Vaccines: 12 Vaccines Regulatory Framework for ...

Sep, 2014 864 pages
Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Review, H2, 2014 Summary GlobalData's clinical trial report, “Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H2, 2014' provides data ... of trials for the key drugs for treating Coronary Artery Disease (CAD) (Ischemic Heart Disease). This report is built using data and ...

Aug, 2014 100 pages
Chronic Thromboembolic Pulmonary Hypertension Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Chronic Thromboembolic Pulmonary Hypertension Global Clinical Trials Review, H2, 2014' provides data ... status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Chronic ...

Aug, 2014 99 pages
Chronic Heart Failure Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Clinical Trials Review, H2, 2014' provides data on the Chronic Heart Failure clinical trial scenario. This report provides elemental information and data ... across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also ...

Aug, 2014 102 pages
Alzheimer's Disease Drug Pipeline, Diagnostics and Biomarkers: New Developments, Growth Areas and Opportunities US$ 3,016.00

... of the drug development pipeline relating to Alzheimer's disease, which has been analysed alongside commercially available or developmental minimally-invasive AD diagnostics and ... studies involving AD patients (and those with (presumed) early-stage disease) and studies published over the last five year, 40,000 ...

Sep, 2014 185 pages
Global Hepatitis B Vaccines Market 2014-2018 US$ 2,500.00

... transient serum sickness-like syndrome, and membranous glomerulonephritis. Perinatal transmission of hepatitis B virus is the most common mode of infection spread. Age of a person ... the present scenario and the growth prospects of the Global Hepatitis B Vaccines market for the period 2014-2018. To calculate the ...

Aug, 2014 91 pages
The US Anti Cancer Drug Market Outlook to 2018 - Demand of Oral Drugs to Drive Growth US$ 900.00

... growth rate can be attributed to an increasing number of drugs being approved by the United States Food and Drug Association along with the increasing ... held a market share of ~% and recorded sales of USD ~ million. The US Anti Cancer Drug Market is expected to grow over the period at a CAGR of 29.4% with ...

Jul, 2014 144 pages
Drug Discovery Technologies - A Global Market Overview US$ 3,060.00

... field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening. Worldwide market for drug discovery technologies explored in this study includes Bioanalytical Assays, Bioinformatics, Cell Based Assays, Genomic Technologies, High Throughput Screening, ...

Aug, 2014 248 pages
Treventis Corporation - Product Pipeline Review - 2014 US$ 1,500.00

... and its locations and subsidiaries The report reviews current pipeline of Treventis Corporation’s human therapeutic division and enlists all their major ... the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Treventis Corporation’s pipeline products ...

Aug, 2014 22 pages
Sol-Gel Technologies Ltd. - Product Pipeline Review - 2014 US$ 1,500.00

... Markets Direct’s, ‘Sol-Gel Technologies Ltd. - Product Pipeline Review - 2014’, provides an overview of the Sol-Gel Technologies Ltd.’s pharmaceutical research ... the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Sol-Gel Technologies Ltd.’s pipeline ...

Aug, 2014 18 pages
NeoPharm Co., Ltd. - Product Pipeline Review - 2014 US$ 1,500.00

... description, key information and facts, and its locations and subsidiaries The report reviews current pipeline of NeoPharm Co., Ltd.’s human therapeutic ... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the NeoPharm Co., Ltd.’s pipeline products ...

Aug, 2014 31 pages
Molecular Templates Inc. - Product Pipeline Review - 2014 US$ 1,500.00

... , key information and facts, and its locations and subsidiaries The report reviews current pipeline of Molecular Templates Inc.’s human therapeutic ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Molecular Templates Inc.’s pipeline products Reasons to ...

Aug, 2014 29 pages
Intezyne, Inc - Product Pipeline Review - 2014 US$ 1,500.00

... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Intezyne, Inc’s pipeline products ... drug targets and therapeutic classes in the Intezyne, Inc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas Exploit ...

Aug, 2014 27 pages
EyeCyte, Inc. - Product Pipeline Review - 2014 US$ 1,500.00

... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the EyeCyte, Inc.’s pipeline products ... drug targets and therapeutic classes in the EyeCyte, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas Exploit ...

Aug, 2014 20 pages
Da Volterra - Product Pipeline Review - 2014 US$ 1,500.00

Summary Global Markets Direct’s, ‘Da Volterra - Product Pipeline Review - 2014’, provides an overview of the Da Volterra’s pharmaceutical research and development focus. This ... and enlists all their major and minor projects The report features product description and descriptive mechanism of action for key ...

Aug, 2014 21 pages
CYATHUS EXQUIRERE PharmaforschungsGmbH - Product Pipeline Review - 2014 US$ 1,500.00

... (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the CYATHUS EXQUIRERE PharmaforschungsGmbH’s pipeline products Reasons ...

Aug, 2014 17 pages
AllTranz, Inc. - Product Pipeline Review - 2014 US$ 1,500.00

... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the AllTranz, Inc.’s pipeline products ... drug targets and therapeutic classes in the AllTranz, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas Exploit ...

Aug, 2014 21 pages
US CNS Disorders Drug Pipeline Insight 2014 US$ 2,400.00

... purchasing Hard Copy License depending on the location. The Central Nervous System (CNS) disorders market in US is one of the largest segments of pharmaceuticals industry ... with launch of novel drugs will drive the growth of CNS disease market in future. “US CNS Disorders Drug Pipeline Insight 2014” Report ...

Aug, 2014 1700 pages
Fatty Liver Disease Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Clinical Trials Review, H2, 2014' provides data on the Fatty Liver Disease clinical trial scenario. This report provides elemental information and data ... conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors ...

Aug, 2014 85 pages
Critical Limb Ischemia Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Clinical Trials Review, H2, 2014' provides data on the Critical Limb Ischemia clinical trial scenario. This report provides elemental information and data ... across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also ...

Aug, 2014 78 pages
Coronary Stenosis Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Trials Review, H2, 2014' provides data on the Coronary Stenosis clinical trial scenario. This report provides elemental information and data relating to the ... of data for the indicated disease. Scope Data on the number of clinical trials conducted in North America, South and Central America, Europe, ...

Aug, 2014 78 pages
Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Trials Review, H2, 2014' provides data on the Coronary Arteriosclerosis clinical trial scenario. This report provides elemental information and data relating to the ... of data for the indicated disease. Scope Data on the number of clinical trials conducted in North America, South and Central America, Europe ...

Aug, 2014 83 pages
Chagas Cardiomyopathy Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Trials Review, H2, 2014' provides data on the Chagas Cardiomyopathy clinical trial scenario. This report provides elemental information and data relating to the ... of data for the indicated disease. Scope Data on the number of clinical trials conducted in North America, South and Central America, Europe, ...

Aug, 2014 60 pages
Global Multiple Sclerosis Drugs Market 2014-2018 US$ 3,000.00

... the present scenario and the growth prospects of the Global Multiple Sclerosis Drugs market for the period 2014-2018. To calculate the market ... Acorda Active Biotech GlaxoSmithKline Glenmark Mitsubishi Tanabe Opexa Pfizer Sanofi Market Driver Unmet Medical Needs For a full, detailed list, view our ...

Aug, 2014 102 pages
Global Meningococcal Vaccines Market 2014-2018 US$ 2,500.00

... to grow at a CAGR of 15.00 percent over the period 2013-2018. Covered in this Report This report covers the present scenario and the ... caused by different serogroups of Neisseria meningitides. TechNavio's report, the Global Meningococcal Vaccines Market 2014-2018, has been prepared based on an in-depth ...

Aug, 2014 78 pages
vasopharm GmbH - Product Pipeline Review - 2014 US$ 1,500.00

... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the vasopharm GmbH’s pipeline products ... drug targets and therapeutic classes in the vasopharm GmbH’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas Exploit ...

Aug, 2014 22 pages
Tacere Therapeutics, Inc. - Product Pipeline Review - 2014 US$ 1,500.00

... disease. Scope The report provides brief overview of Tacere Therapeutics, Inc. including business description, key information and facts, and its ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Tacere Therapeutics, Inc.’s pipeline products Reasons to ...

Jul, 2014 27 pages
Phenomenome Discoveries, Inc. - Product Pipeline Review - 2014 US$ 1,500.00

... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Phenomenome Discoveries, Inc.’s pipeline products Reasons ... Assess the growth potential of Phenomenome Discoveries, Inc. in its therapy areas of focus Identify new drug targets and therapeutic classes in the ...

Jul, 2014 20 pages
1 2 3 4 5 >
Skip to top